Impact of RAS-MAPK Pathway Genetic Alterations on Radiotherapy Response in Metastatic Lung Adenocarcinoma
Gustav Y Cederquist1, Erik S Anderson1, Eric Lis2
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
JCO Precision Oncology
|December 5, 2025
Summary
Driver gene alterations in the RAS-MAPK pathway, such as NF1 and BRAF mutations, are linked to higher rates of local failure in non-small cell lung cancer (NSCLC) spine metastases treated with radiotherapy. These findings suggest potential biomarkers for personalizing radiation therapy.
Area of Science:
- Oncology
- Genetics
- Radiation Oncology
Background:
- Metastatic non-small cell lung cancer (NSCLC) often requires radiotherapy (RT) for spine metastases.
- Predicting treatment response in NSCLC patients is crucial for optimizing outcomes.
- Driver gene alterations are key in NSCLC pathogenesis and treatment resistance.
Purpose of the Study:
- To investigate the association between driver gene alterations in NSCLC spine metastases and local tumor control after RT.
- To identify specific genetic mutations that may predict radioresistance or radiosensitivity.
Main Methods:
- Retrospective analysis of 181 NSCLC patients who received RT for spine metastases and underwent genetic profiling.
- Statistical analysis of driver gene mutations and local failure incidence, including competing risk analysis.
- In vitro validation using CRISPR-engineered NSCLC cell lines to assess radioresistance.
Main Results:
- Patients with NF1 or BRAF driver alterations showed significantly higher 3-year local failure rates after RT.
- NF1 loss-of-function mutations conferred radioresistance in vitro.
- RAS-MAPK pathway driver alterations were associated with 53% of local failures and increased risk, even with stereotactic body RT.
Conclusions:
- Driver alterations within the RAS-MAPK signaling pathway contribute to radioresistance in metastatic NSCLC spine metastases.
- These genetic alterations can potentially serve as biomarkers for tailoring RT strategies.
- Targeting RAS-MAPK pathway alterations may enhance radiosensitivity and improve treatment efficacy.
More Related Videos
Related Concept Videos
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K


